Tag: Impella

SCAI 2020: PROTECT III shows placing Impella prior to high-risk PCI...

Data from more than 1,000 patients presented during the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time)...

Abiomed acquires novel ECMO developer Breethe

Abiomed (maker of the Impella heart pump) has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system. A press release reports that...

COVID-19: Edwards pauses enrolment in mitral and tricuspid trials to allow...

Edwards Lifesciences has temporarily paused new enrolments in its active pivotal clinical trials of its transcatheter mitral and tricuspid therapies in response to ongoing...
impella in preventing heart failure in stemi patients

New trial to evaluate role of Impella in preventing heart failure...

A pivotal, multicentre clinical trial is exploring the use of an Impella heart pump (Abiomed) to unload the left ventricle for 30 minutes prior...

Abiomed announces PROTECT III clinical data for protected PCI with Impella

Abiomed has announced the results of PROTECT III, an ongoing, prospective, single-arm US Food and Drug Administration (FDA) post-market approval (PMA) study for Impella...

Challenges of conducting a randomised clinical trials to prove the impact...

Mechanical circulatory support is frequently used to stabilise patient haemodynamics in desperate situations of circulatory failure to increase and maintain end organ perfusion.1 Of...

CE mark for cloud-based monitoring platform Impella Connect

Abiomed has achieved the CE mark for Impella Connect, which—a press release reports—is the first-of-its kind cloud-based technology that enables secure, real-time, remote viewing...

Abiomed receives expanded FDA approve for high-risk PCI procedures

Abiomed has received an expanded US FDA premarket approval for the Impella 2.5 and Impella CP heart pumps during elective and urgent high-risk percutaneous coronary...

FDA grants Abiomed pre-market approval for is Impella RP for right...

Abiomed has received FDA pre-market approval for its Impella RP heart pump. Culminating from five years of research, according to a press release, this...

Patient enrolled in STEMI DTU feasibility study

Abiomed announced today the enrolment of the first patient in the FDA approved prospective feasibility study, STEMI Door to Unloading (DTU) with Impella CP...

Study indicates that Impella heart pump reduces acute kidney injury during...

A new study published in Circulation Research finds that the use of haemodynamic support with Impella 2.5 heart pump during high-risk percutaneous coronary intervention...

FDA pre-market approval for the Impella heart pump for high-risk PCI...

Abiomed has expanded its FDA pre-market approval for Impella heart pump use in high-risk percutaneous coronary interventions (PCI) to include its Impella CP heart...

Japan approves Abiomed’s Impella 2.5 and Impella 5.0 heart pumps

Abiomed has announced that its heart pumps Impella 2.5 and Impella 5.0 have received Pharmaceuticals and Medical Devices Agency (PMDA) approval from the Japanese...